AMG
52
3
AIZ
66
3
DGX
29
2
SYK
57
6
FIS
48
5
NUE
41
2
RSG
56
2
GLW
48
4
AEP
43
-4
V
76
8
A
47
4
VRSK
59
5
NTRS
44
5
ABBV
48
2
CHD
37
5
WMB
62
2
MRK
27
2
VRTX
49
2
LB
30
11
MKC
53
2
AMG
52
3
AIZ
66
3
DGX
29
2
SYK
57
6
FIS
48
5
NUE
41
2
RSG
56
2
GLW
48
4
AEP
43
-4
V
76
8
A
47
4
VRSK
59
5
NTRS
44
5
ABBV
48
2
CHD
37
5
WMB
62
2
MRK
27
2
VRTX
49
2
LB
30
11
MKC
53
2
Financhill
Back

Range Cancer Therapeutics ETF Stock Predictions

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
30

CNCR
Range Cancer Therapeutics ETF

Last Price:
$12.39
Seasonality Move:
-2.56%

7 Day Trial

ALL ACCESS PASS

$ 7

2025 Gold Forecast: A Perfect Storm for Demand

Discover our Gold Price Outlook for 2025--FREE--here

Range Cancer Therapeutics ETF Stock Forecast

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 5.5% based on the past 9 years of stock performance.
  • Range Cancer Therapeutics ETF has fallen lower in 5 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%
  • Is Range Cancer Therapeutics ETF Stock Undervalued?
    The current Range Cancer Therapeutics ETF [CNCR] share price is $12.35. The Score for CNCR is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.
  • CNCR is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.

Will Range Cancer Therapeutics ETF Stock Go Up Next Year?

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 5.5% based on the past 9 years of stock performance.

Range Cancer Therapeutics ETF Stock Rating

Sell
30
Range Cancer Therapeutics ETF (CNCR) is a Sell

Is Range Cancer Therapeutics ETF overpriced?

  • Range Cancer Therapeutics ETF has fallen lower in 5 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%

Range Cancer Therapeutics ETF Stock Price History

Is CNCR stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and CNCR is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Industry:
Sector:
Type:
etf
Website:

52-Week Data

52-Week High:
17.96
52-Week Low:
11.87

Prediction Charts

Market Cap:
0
Price in USD:
12.35
Volume:
547
Beta:
1.10

Technical Analysis

SMA50:
14.26
SMA100:
14.50
SMA200:
14.75
52-Wk Change:
-5.73%

Stock Predictions

  • Is Range Cancer Therapeutics ETF stock public?
    Yes, Range Cancer Therapeutics ETF is a publicly traded company.
  • What is the Range Cancer Therapeutics ETF stock quote today?
    The Range Cancer Therapeutics ETF stock price is 12.35 USD today.
  • How to buy Range Cancer Therapeutics ETF stock online?
    You can buy Range Cancer Therapeutics ETF shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-3 14.49 14.15 14.49 14.19
Dec-4 14.15 13.96 14.15 13.99
Dec-5 13.68 13.66 13.85 13.62
Dec-6 14.04 14.06 14.04 14.04
Dec-9 14.55 14.19 14.55 14.14
Dec-10 14.14 13.74 14.14 13.81
Dec-11 13.89 13.67 13.89 13.60
Dec-12 13.49 13.01 13.50 13.05
Dec-13 12.94 12.68 12.94 12.62
Dec-16 12.88 12.81 12.92 12.81
Dec-17 12.68 12.66 12.70 12.61
Dec-18 12.62 12.02 12.63 11.95
Dec-20 11.87 12.09 12.21 11.87
Dec-24 12.33 12.35 12.35 12.23

Range Cancer Therapeutics ETF Earnings

Data Unavailable

Range Cancer Therapeutics ETF Forecast Revenue Growth

Data Unavailable

* Range Cancer Therapeutics ETF stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.